Entries of Abhyankar, Sunil on the publication server
 | Up a level |
Jump to: 2023
Number of items: 1.
2023
Al Malki, Monzr M., London, Kaitlyn, Baez, Janna, Akahoshi, Yu 
, Hogan, William J. , Etra, Aaron, Choe, Hannah, Hexner, Elizabeth , Langston, Amelia , Abhyankar, Sunil, Ponce, Doris M., DeFilipp, Zachariah, Kitko, Carrie L., Adekola, Kehinde, Reshef, Ran, Ayuk, Francis, Capellini, Alexandra, Chanswangphuwana, Chantiya, Eder, Matthias, Eng, Gilbert, Gandhi, Isha, Grupp, Stephan, Gleich, Sigrun, Holler, Ernst, Javorniczky, Nora Rebeka, Kasikis, Stelios, Kowalyk, Steven, Morales, George, Özbek, Umut, Rösler, Wolf, Spyrou, Nikolaos, Yanik, Gregory, Young, Rachel, Chen, Yi-Bin, Nakamura, Ryotaro, Ferrara, James L. M. and Levine, John E.
(2023)
Phase 2 study of natalizumab plus standard corticosteroid treatment for high-risk acute graft-versus-host disease.
Blood Advances 7 (17), pp. 5189-5198.
Fulltext not available.
, Hogan, William J. , Etra, Aaron, Choe, Hannah, Hexner, Elizabeth , Langston, Amelia , Abhyankar, Sunil, Ponce, Doris M., DeFilipp, Zachariah, Kitko, Carrie L., Adekola, Kehinde, Reshef, Ran, Ayuk, Francis, Capellini, Alexandra, Chanswangphuwana, Chantiya, Eder, Matthias, Eng, Gilbert, Gandhi, Isha, Grupp, Stephan, Gleich, Sigrun, Holler, Ernst, Javorniczky, Nora Rebeka, Kasikis, Stelios, Kowalyk, Steven, Morales, George, Özbek, Umut, Rösler, Wolf, Spyrou, Nikolaos, Yanik, Gregory, Young, Rachel, Chen, Yi-Bin, Nakamura, Ryotaro, Ferrara, James L. M. and Levine, John E.
(2023)
Phase 2 study of natalizumab plus standard corticosteroid treatment for high-risk acute graft-versus-host disease.
Blood Advances 7 (17), pp. 5189-5198.
Fulltext not available.